FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

92 letters match. Newest first.

  1. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  2. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  3. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  4. Seaway Pharma Inc.

    FDA cited Seaway Pharma for manufacturing-quality rule violations in OTC oral liquid drugs, including release and component-testing failures.

    High risk
  5. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  6. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  7. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  8. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  9. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  10. The Tranzonic Companies/Innocore Sales & Marketing Inc.

    FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.

    High risk
  11. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  12. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  13. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk
  14. ABBE Laboratories, Inc.

    FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.

    High risk
  15. Gussyup LLC dba Private Label Grooming

    FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.

    High risk
  16. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  17. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  18. Xtreme Tools International, Inc.

    FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.

    High risk
  19. Dynamic Blending Specialists, Inc.

    FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.

    High risk
  20. Laboratoire Druide Inc.

    FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.

    High risk
  21. Amish Origins Management, LLC

    FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.

    High risk
  22. Product Society LLC

    FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.

    High risk
  23. Dyno Manufacturing, Inc.

    Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.

    High risk
  24. BEO Pharma Inc. dba BEO Pharmaceuticals Inc.

    FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.

    High risk
  25. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  26. Linghai ZhanWang Biotechnology Co., Ltd

    Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.

    High risk
  27. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  28. Strukmyer LLC dba Strukmyer Medical

    Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

    High risk
  29. Imperial Palace Commodity -Dongguan- Co., Ltd.

    FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

    High risk
  30. Kardesler Ucan Yaglar Sanayi Anonim Sirketi

    Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

    High risk
  31. Dr. Brite, LLC

    FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.

    High risk
  32. LCC Ltd.

    FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

    High risk
  33. Hangzhou Huiji Biotechnology Co., Ltd.

    FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.

    High risk
  34. Multaler et Cie SAS

    FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.

    High risk
  35. Diora Kimya Sanayi ve Ticaret Limited Sirketi

    FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.

    High risk
  36. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  37. Wittman Pharma, Inc.

    FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.

    High risk
  38. TJA Health, LLC

    FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.

    High risk
  39. AnuMed International, LLC

    FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

    High risk
  40. Intercos Europe S.p.A

    FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.

    High risk
  41. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  42. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  43. Art of Beauty Company, Inc.

    FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

    High risk
  44. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk
  45. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  46. Landy International

    FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.

    High risk
  47. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  48. Seatex, LLC

    FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.

    High risk
  49. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  50. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk